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Original Article
Angiotensin converting enzyme
inhibitors do not increase the risk
of poor outcomes in COVID-19 disease.
A multi-centre observational study
Khurram Shahzad Khan1,* , Hamish Reed-Embleton2,* ,
Jen Lewis3, Pamela Bain4 and Sajid Mahmud5
Abstract
Background and aims: Hypertension is associated with an increased risk of severe outcomes with COVID-19 disease.
Angiotensin Converting Enzyme (ACE) inhibitors are widely used as a first line medication for the treatment of hyper-
tension in the UK, although their use was suggested in early reports to increase the risk associated with SARS-CoV-2
infection.
Methods: A prospective cohort study of hospitalised patients with laboratory confirmed COVID-19 was conducted
across three hospital sites with patients identified on the 9th April 2020. Demographic and other baseline data were
extracted from electronic case records, and patients grouped depending on ACE inhibitor usage or not. The 60-day all-
cause mortality and need for intubation compared.
Results: Of the 173 patients identified, 88 (50.8%) had hypertension. Of these 27 (30.7%) used ACE inhibitors. We did
not find significant differences in 60-day all-cause mortality, the requirement for invasive ventilation or length of stay
between our patient cohorts after adjusting for covariates.
Conclusion: This study contributes to the growing evidence supporting the continued use of ACE inhibitors in COVID-
19 disease, although adequately powered randomised controlled trials will be needed to confirm effects.
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Introduction
The SARS-CoV-2 pandemic has resulted in an unprec-
edented challenge for global healthcare systems. In
Scotland there has been over 15,000 cases with over
2,400 deaths by 10/06/2020.1 Multiple risk factors for
poor outcomes have been identified, most consistently
increasing age and underlying health conditions.2
Large scale observational studies looking at the char-
acteristics in hospitalised patients in the UK,2 Italy,3
the USA4 and China5 have consistently reported chron-
ic cardiac disease or hypertension as the most common
comorbidity associated with infection.
In Scotland approximately 30% of adults have
hypertension, although the rates in the 2 least deprived
quintiles is only around 24%.6 The National Institute
of Health and Care Excellence (NICE) guidelines in
the UK recommend Angiotensin Converting Enzyme
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(ACE) inhibitors as one of the first line therapies for
the management of patients with hypertension.7 ACE is
a functional part of the Renin-Angiotensin system
(RAS) whose primary roles include vasoconstriction,
raising blood pressure, promotion of inflammation,
and fibrosis.8 ACE2 receptors, which are used by coro-
naviruses to gain entry to target cells, antagonise these
effects and are found in the heart, kidneys, lung alve-
olar type II epithelial cells and testes.8 Early reports
suggested that ACE inhibitors may lead to a compen-
satory upregulation of ACE2, and that the continued
use of these medications may have deleterious effects
on patients with COVID-19 disease.9
Currently, the European Society of Cardiology con-
sider that ACE inhibitors are safe and support their
continued usage according to national guidelines, and
note the lack of data supporting harmful effect.10 In the
UK, NICE also cite the poor quality of available stud-
ies and were unable to conclude whether ACE inhib-
itors increase the risk of infection or severe outcomes
with SARS-CoV-2 infection.11
We aim to explore the potential influences of ACE
inhibitors on a hospitalised patient population with
hypertension and COVID-19 disease and determine
whether continued usage may negatively impact patient
outcomes.
Material and methods
This was a prospective cohort study carried out on all
hospitalized patients with real-time transcriptase poly-
merase chain reaction (RT-PCR) confirmed COVID-
19, on a single day (Friday the 9th April 2020).
Patients from three acute hospitals in a single
National Health Service (NHS) Trust in Scotland serv-
ing a population of 658,130 with over 1,660 in-patient’s
bed capacity were included. COVID-19 positive
patients were identified from TrakCare Electronic
Medical Record System. The RT-PCR swabs were car-
ried out on symptomatic patients or patients suspected
of having COVID-19. Patients with an initial negative
swab who later during their hospital admission
had a positive swab were also included in the study.
The electronic case notes were analysed for baseline
characteristics; age, gender, co-morbidities and admis-
sion blood test.
Scottish Index of Multiple Deprivation (SIMD)12
score and Age-Adjusted Charlson Comorbidity Index
(ACCI)13 score were analyzed. SIMD utilises postcode
to calculate a score of relative deprivation taking into
account income, health, education crime, housing,
employment and access to services. The ACCI is a
score that predicts 10 year mortality, it includes 19
medical conditions, and provides an age adjusted
score for every year above 50 years of age. Patients
with the past medical history of hypertension were
included and those without hypertension excluded.
Patients were divided into two groups based on if
they were receiving ACE inhibitors or not.
Critical care was defined as care provided above
general ward level. Mortality was in-patient all-cause
mortality. All patients were followed up for at least
60 days from admission or until discharge or death.
Poor outcome was defined as either need for intubation
and/or death. This was to account for those patients
who were critically ill but not suitable for intubation
and were Do Not Attempt Resuscitation and/or palli-
ated. Patients transferred to off-site rehabilitation unit
were considered to be discharged.
Statistical analyses
Univariate analyses were carried out to explore wheth-
er differences existed in outcomes between hypertensive
patients with and without treatment with ACE inhib-
itors. Subsequently, multivariate analyses were per-
formed to examine whether any differences between
groups remained after controlling for covariates.
A logistic regression was performed to explore whether
treatment with ACE inhibitors increase the risk of intu-
bation and ventilation. A multivariate linear regression
was used to explore effects on length of stay, and a
multivariate Cox’s proportional hazards model was
used to explore the effects of ACE inhibitors on
survival.
This study was registered with the NHS
Lanarkshire’s Clinical Quality Project, project id:
13139. As this was an observational study, patient con-
sent was not required.
Results
There were 173 patients identified with positive RT-
PCR, of these 88 (50.8%) had hypertension. Of the
hypertensive patients 50 (56.8%) were male, with a
mean age of 72 (13.5) years. Summary demographics
and baseline investigation results were calculated, and
differences explored with univariate analyses (Table 1).
A total of 19 deaths occurred in 60 days. We did not
find significant differences in the outcomes between the
cohorts using ACE inhibitors and those who were not
(Table 2). Figure 1 represents an unadjusted Kaplan-
Meier plot comparing survival probabilities in those
using ACE inhibitors and those who are not.
Treatment with ACE inhibitors remained insignifi-
cant in predicting invasive ventilation when controlling
for ACCI and sex. Of the included covariates, only
ACCI was significant (OR¼ 0.551, p< 0.001) suggest-
ing that patients with a higher ACCI were less likely to
be admitted to ICU. Treatment with ACE inhibitors
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remained insignificant on 60-day all-cause mortality
after adjusting for sex, ICU admission, and age adjust-
ed ACCI. Treatment with ACE inhibitors again
remained insignificant for predicting LOS when con-
trolling for covariates, although ACCI (p¼ 0.012),
and admission to ICU (p¼ 0.014) were significant pre-
dictors of long LOS.
Discussion
This study provides a comprehensive assessment of
the influence of ACE inhibitors on poor COVID-19
disease outcomes in a hospitalised population. We
did not find significant differences in mortality, the
requirement for invasive ventilation or length of stay
after adjusting for covariates including sex and age-
adjusted Charlson comorbidity index scores. This
data contributes to the evidence suggesting the
safe continued use of ACE inhibitors in patients as
Table 2. Comparison of outcomes.
All participants
(n¼ 88)
No ACE inhibitors
(n¼ 61)
ACE inhibitors
(n¼ 27) Differencea 95% CI p
Critical care admission (%) 18 (20.45) 9 (14.75) 9 (33.33) 0.24 –0.04, 0.53 0.088
Intubated and ventilated (%) 12 (13.64) 7 (11.48) 5 (18.52) 0.13 –0.22, 0.47 0.582
In-patient mortality (%)b 19 (21.59) 14 (22.95) 5 (18.52) –0.06 –0.32, 0.20 0.853
Median LOS (IQR)b 17 (8, 24) 17 (10, 29) 14 (8, 22) 2.00 –3.00, 8.00 0.337
ACE: angiotensin converting enzyme; LOS: length of stay; IQR: interquartile range.
aDifference column shows location difference estimate for numeric variables, proportion difference estimate for categorical variables.
bVariables missing data from remaining in-patients (n¼2).
Table 1. Demographics and baseline investigation results.
All participants
(n¼ 88)
No ACE inhibitors
(n¼ 61)
ACE inhibitors
(n¼ 27) Differencea 95% CI p
Mean age (SD) 72.03 (13.51) 74.61 (13.33) 66.22 (12.25) 9.00 3, 15 0.006b
N Male (%) 50 (56.82) 30 (49.18) 20 (74.07) 0.22 0.01, 0.42 0.052
Median ACCI (IQR) 4.5 (3, 6) 5 (4, 7) 3 (2, 5) 2.00 1–3 0.002b
Medianc deprivation
decile (IQR)
4 (2, 6) 4 (2, 6) 4 (2.5, 7) –1.00 –2, 0 0.247
Median Cr (IQR) 93 (70.8, 115.2) 94 (67, 115) 91 (76.5, 115) –1.00 –17, 15 0.968
Median CRP (IQR) 57.5 (31.8, 132) 52 (28, 124) 85 (46.5, 144.5) –19.00 –49, 8 0.182
Median lymphocytes (IQR) 0.85 (0.7, 1.2) 0.9 (0.7, 1.3) 0.8 (0.7, 1.1) <0.01 –0.2, 0.2 0.841
Median neutrophils (IQR) 5.95 (4, 8) 5.6 (3.9, 7.6) 6.4 (4.2, 9.2) –0.60 –2, 0.9 0.455
Median platelets (IQR) 205.5 (161.2, 257.5) 208 (171, 255) 182 (151.5, 258) 11.00 –28, 52 0.566
N eGFR >59 (%) 48 (54.55) 31 (50.82) 17 (62.96) 0.10 –0.11, 0.32 0.411
N CXR> 1 (%)c 40 (45.45) 25 (40.98) 15 (55.56) 0.11 –0.11, 0.33 0.366
ACE: angiotensin converting enzyme; SD: standard deviation; ACCI: age-adjusted Charlson Comorbidity Index; IQR: interquartile range; Cr: creatinine;
CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; CXR: Chest X-ray.
aDifference column shows location difference estimate for numeric variables, proportion difference estimate for categorical variables
bSignificant at p<0.01.
‡Variables had missing values (Dep. Decile¼ 1, CXR¼ 2).
Figure 1. Unadjusted Kaplan-Meier plot comparing inpatients
using ACE inhibitor and those who were not. Crosses on this
plot represent patient discharges.
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per national guidelines for the management of
hypertension.
Early reports on the use of ACE inhibitors were
inconsistent with studies suggesting they could be ben-
eficial, harmful or have no effect in COVID-19 dis-
ease.14–16 Sommerstein et al., postulated that ACE
inhibitors may have a biphasic effect on patients with
those taking this medication being more at risk of
infection, but then more likely to have less severe dis-
ease.17 Our data give no good evidence of significant
differences, but were under-powered to determine small
differences.
Despite SARS-CoV-2 tropism for the pulmonary
parenchyma, in the most severe cases multiorgan fail-
ure develops.18 The vasodilatory, anti-inflammatory,
anti-proliferative and antifibrotic effects of ACE2
receptors may in fact, partially counterbalance the del-
eterious systemic effects often observed in COVID-19
disease.19,20 In experimental conditions, the administra-
tion of ACE inhibitors upregulated the activity of
ACE2 receptors.21 It is now thought that ACE inhib-
itors may exert a protective effect against the develop-
ment of acute lung injury in infections with SARS
coronaviruses, by limiting the dysregulation of mecha-
nisms that lead to acute respiratory distress and endo-
thelial damage.22,23
SARS-CoV-2 appears to have a 10-20 fold greater
affinity for ACE2 receptors, compared with the SARS-
CoV virus which caused the 2003 SARS outbreak,
which is suggested as one of the contributing factors
for its effective human-to-human transmission.24 In
propensity score-matched analyses in an outpatient
population with positive SARS-CoV-2 infection, ACE
inhibitors resulted in decreased hospital admissions
and did not confer any added risk of mortality to inpa-
tients.23 Our study is unable to determine the potential
increased risk of infection in those who were using
ACE inhibitors in the community as we only collected
data in hospitalised patients. Inhibitors of the RAS
system do not play a direct antiviral role, but act indi-
rectly though regulation of the immune system and
inflammatory responses.25
Our study adds to other studies which support the
safe continuation of ACE inhibitors during the current
pandemic.18,23,25–28 Further adequately powered trials
are required to determine any protective effect of ACE
inhibitors in patients with hypertension.
Our cross-sectional methods of identifying all
sequential admissions during a defined time period ena-
bles a valid representation of the hospital population in
Scotland and data was collected across all departments,
but we acknowledge that generalisation of our findings
is limited by small sample size. Although data was col-
lected across three hospital sites, they were all based in
a single NHS health board and this method of data
collection will also be subject to a degree of length-
time bias.29 Recruiting patients from hospitals,
care homes and the community as well as reaching a
greater sample size with a control population, would
improve the validity and generalisability of the data.
When examining mortality, Schoenfield tests revealed
deviations from proportionality for ACCI (p< 0.05).
However, stratification on ACCI was not possible
due to a low number of deaths among those with low
ACCI scores. Results are therefore reported for the full
model, but these should be interpreted with caution.
Conclusion
We did not find any negative effects on severe out-
comes in our hypertensive patient cohort using ACE
inhibitors compared with those who did not.
Adequately powered trials are needed to determine
the optimal treatment of hypertension during the
COVID pandemic.
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